In addition, we used LY-294002 (AKT inhibitor) and Rapamycin (mTOR inhibitor) to evaluate the effects of inhibitors alone or in combination with overexpression of PDHK1-241aa on the tumor biological behavior of ccRCC cells. This evidence concerns the gene AKT1 and nonpapillary renal cell carcinoma.